Primer Sjögren Sendromlu Hastalarda İnterlökin-38 Düzeyi

Year 2022, Volume: 55 Issue: 2, 78 - 80, 31.08.2022

Selcan Gültuna , Sevinc Can , Fevzi Nuri Aydin

https://doi.org/10.20492/aeahtd.1035777

Abstract

Amaç: İnterlökin (IL)-38, otoimmün hastalıklarda rol oynamaktadır. Bununla birlikte, birincil Sjögren sendromunun gelişiminde IL-38'in rolü hakkında yeterli bilgi bulunmamaktadır. Bu çalışma, IL-38'in primer Sjögren sendromundaki rolünü ve klinik ilişkisini değerlendirmeyi amaçladı.
Yöntemler: 2019-2020 yılları arasında primer Sjögren sendromlu 40 hasta ve 39 sağlıklı katılımcı çalışmaya dahil edildi. IL-38'in serum seviyesi, tüm katılımcılarda ELISA ile ölçüldü. IL-38'in serum seviyeleri klinik ve laboratuvar özellikleri ile karşılaştırıldı.
Bulgular: Primer Sjögren sendromu hastaları ve kontrol grubu, serum IL-38 düzeyleri açısından benzerdi (58.0 pg/ml, min-maks: 0-641.0 ve 55.0 ng/ml, min-maks: 0- 338.0; p=0.511). Serum IL-38 düzeyi ile SSDAI arasında anlamlı bir ilişki bulunmadı (r=-0.104, p=0.523). IL-38 düzeyi RF ile orta derecede negatif (r=-0.364, p=0.021) ve CRP ile pozitif korelasyon (r=0.321, p= 0.044) bulundu.
Sonuç: IL-38 Primer Sjögren sendromlu hastalarda CRP ve RF ile ilişkili bulunmuştur. IL-38'in gelecekteki rolü, pSS'nin spesifik klinik belirtileri için bir biyobelirteç olabilir.

Keywords

Hastalık aktivitesi, interlökin-38, primer Sjögren sendromu, T yardımcı hücre-17

Supporting Institution

yok

Investigation of Interleukin-38 in patients with primary Sjögren’s Syndrome

Abstract

Aim: Interleukin-38 has been involved as an inflammatory mediator in rheumatic diseases. However, little is known about the role of IL-38 in the development of primary Sjögren’s syndrome. The present study aimed to evaluate the role of IL-38 in primary Sjögren’s syndrome and its clinical relevance.
Material and Method:Between 2019 and 2020, 40 patients with primary Sjögren’s syndrome and 39 healthy participants were included in the study. The serum IL-38 level was measured by ELISA in all participants. The serum levels of IL-38 were compared with clinical and laboratory features.
Results:The serum IL-38 levels between the patients with primary Sjögren’s syndrome and the controls were similar (58.0 pg/ml, min-max: 0-641.0 vs. 55.0 ng/ml, min-max: 0-338.0; p=0.511). No significant correlations were found between serum IL-38 level and SSDAI (r=-0.104, p=0.523). IL-38 level was mildly negatively correlated with RF (r=-0.364, p=0.021) and positively correlated with CRP (r=0.321, p= 0.044).
Conclusion:The correlation of IL-38 with CRP and RF should be considered because it might be important clues for contribution to the disease process. IL-38 might be relevant to the heterogeneous nature of PSS and the future role of IL-38 might be a biomarker for specific clinical manifestations of pSS.

Keywords

disease activity, interleukin-38, primary Sjögren’s syndrome, Th-17 cells

References

• 1. Yuan X, Peng X, Li Y, et al. Role of IL-38 and its related cytokines in inflammation. Mediators of inflammation. 2015;2015.
• 2. Xu W-D, Su L-C, He C-S, et al. Plasma interleukin-38 in patients with rheumatoid arthritis. International immunopharmacology. 2018;65:1-7.
• 3. Xie L, Huang Z, Li H, Liu X, et al. IL-38: A new player in inflammatory autoimmune disorders. Biomolecules. 2019;9(8):345.
• 4. Akdis M, Aab A, Altunbulakli C, et al. Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β, and TNF-α: Receptors, functions, and roles in diseases. Journal of Allergy and Clinical Immunology. 2016;138(4):984-1010.
• 5. Xia H-s, Liu Y, Fu Y, et al. Biology of interleukin-38 and its role in chronic inflammatory diseases. International Immunopharmacology. 2021;95:107528.
• 6. van de Veerdonk FL, de Graaf DM, Joosten LA, et al. Biology of IL‐38 and its role in disease. Immunological reviews. 2018;281(1):191-6.
• 7. Xu F, Lin S, Yan X, et al. Interleukin 38 protects against lethal sepsis. The Journal of infectious diseases. 2018;218(7):1175-84.
• 8. Garraud T, Harel M, Boutet M-A, et al. The enigmatic role of IL-38 in inflammatory diseases. Cytokine & growth factor reviews. 2018;39:26-35.
• 9. Matsui K, Sano H. T helper 17 cells in primary Sjögren’s syndrome. Journal of clinical medicine. 2017;6(7):65.
• 10. Ciccia F, Accardo‐Palumbo A, Alessandro R, et al. Interleukin‐36α axis is modulated in patients with primary Sjögren's syndrome. Clinical & Experimental Immunology. 2015;181(2):230-8.
• 11. Luo D, Chen Y, Zhou N, et al. Blockade of Th17 response by IL-38 in primary Sjögren’s syndrome. Molecular Immunology. 2020;127:107-11.
• 12. Vitali C, Bombardieri S, Jonsson R, et al. European Study Group on Classification Criteria for Sjögren's Syndrome. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. 2002.
• 13. Seror R, Bootsma H, Saraux A, et al. Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Annals of the rheumatic diseases. 2016;75(2):382-9.
• 14. Xu W-D, Huang A-F. Role of interleukin-38 in chronic inflammatory diseases: a comprehensive review. Frontiers in immunology. 2018;9:1462.
• 15. Dehghan A, Dupuis J, Barbalic M, et al. Meta-analysis of genome-wide association studies in> 80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation. 2011;123(7):731-8.
• 16. Maślińska M, Mańczak M, Kwiatkowska B. Usefulness of rheumatoid factor as an immunological and prognostic marker in PSS patients. Clinical rheumatology. 2019;38(5):1301-7.
• 17. Imgenberg-Kreuz J, Rasmussen A, Sivils K, et al. Genetics and epigenetics in primary Sjögren’s syndrome. Rheumatology. 2021;60(5):2085-98.
• 18. Han M-M, Yuan X-R, Shi X, et al. The Pathological Mechanism and Potential Application of IL-38 in Autoimmune Diseases. Frontiers in Pharmacology. 2021:2306.
• 19. Ciccia F, Guggino G, Rizzo A, et al. Potential involvement of IL-22 and IL-22-producing cells in the inflamed salivary glands of patients with Sjögren's syndrome. Annals of the rheumatic diseases. 2012;71(2):295-301.